Metastatic Breast Cancer

I’m working through one of the toughest times of my life. Perserverance is one of the many things that cancer has taught me.

The FDA approval of Trodelvy for patients with HR-positive, HER2-negative metastatic breast cancer provides patients with another treatment option after hormone therapy and standard chemotherapy.

After I was diagnosed with stage 4 breast cancer, clinicians told me I wouldn’t make it to my 35th birthday, but I recently did — and look forward to celebrating many more.

The new year brings reflection on living fully with cancer.

The Food and Drug Administration approved Trodelvy for patients with pretreated, unresectable HR-positive, HER2-negative metastatic breast cancer.

Last month, I learned that the treatment for my metastatic breast cancer stopped working, but was thrilled to learn about Enhertu — a new drug for a new subset of patients with breast cancer — as the next line of therapy.

After I was diagnosed with cancer, some people “ghosted” me, but my dog, Iris, never did.

As we enter 2023, I’m looking at life a bit differently, and will prioritize things that make me happy.

Having cancer care denied or delayed is not a harmless situation when your life is on the line.

After being diagnosed with cancer, my love for December is not just Christmas.

Improvements may not be seen right away, but patients with non-metastatic breast cancer should stay compliant to practicing yoga to possibly improve quality of life, according to an expert.

I’ve realized that my forgetfulness and business of working multiple jobs through cancer might have actually helped my mental health.

I had a wonderful time at a recent breast cancer walk, until I got home and found a bracelet with a raunchy saying on it in my survivor’s gift bag.

With a little luck and a lot of coordination, I managed to create an excellent and comprehensive cancer care team in the least populated state in the country.

Since I have stage 4 breast cancer, I wanted an oncologist affiliated with a research institution. However, I hated the prospect of frequent long drives for care. Luckily, I got the best of both worlds.

When people say. “It’s just $35 to see a specialist,” they miss the entire issue of cancer-related financial toxicity.

The Food and Drug Administration granted a priority review to Trodelvy for previously treated locally advanced or metastatic HR-positive, HER2-negative breast cancer.

I wish “Pinktober” was more about saving the people who will die from breast cancer and less about pink ribbons and sexualizing the disease.

From the death of standup comedian and "Love Goddess" Judy Tenuta to professional sports hall-of-famers discussing their cancer, here’s what’s happening in the cancer space this week.

On the same day that I learned of my cancer progression, I also found out I had COVID-19. Here’s how I handled that dark period of life.

Extra years with my family meant missing out on a free trip granted to patients with cancer who have children under the age of 18 — and I’m OK with that.

As “Pinktober” approaches, I’m spreading the message that breasts are not needed to live a full life after breast cancer surgery.

Compared to physician’s choice of treatment, Trodelvy improved survival and quality of life in pretreated patients with HR positive/HER2 negative metastatic breast cancer.

I’ve channeled my cancer-related anger into advocacy, and made a “living list” of things I want to accomplish.

Trodelvy bested chemotherapy for progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer.

I’m giving cancer’s “battle language” an update and focusing my survivorship plan on emotional wellbeing and honesty.

The death of “Grease” star Olivia Newton-John from metastatic breast cancer has triggered discussions about the specifics of the disease. Here, CURE® details what metastatic breast cancer is.

A patient with metastatic breast cancer recalls the emotional experience of being among the thousands of attendees who gave a standing ovation in an auditorium in Chicago when the results of the phase 3 DESTINY-Breast04 trial — which recently led to the FDA approval of Enhertu in HER2-low disease — were presented at the 2022 ASCO Annual Meeting.

If approved, Enhertu may “redefine how we classify and treat metastatic breast cancer,” according to a representative from the drug’s manufacturer.

This year, I returned to the American Society of Clinical Oncology meeting, where I heard about the latest advancements in cancer care, as well as met with fellow patients and advocates.